Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 5

In today’s AI news, Mercor, the AI recruiting startup founded by three 21-year-old Thiel Fellows, has raised $100 million in a Series B round, the company confirmed to TechCrunch. Menlo Park-based Felicis led the round, valuing Mercor at $2 billion — eight times its previous valuation. Existing investors Benchmark and General Catalyst, as well as DST Global and Menlo Ventures participated.

In other advancements, GPT-4.5 could arrive as soon as next week, as Microsoft gets ready to host OpenAI’s latest artificial intelligence models.

Microsoft engineers are currently readying server capacity for OpenAI’s upcoming GPT-4.5 and GPT-5 models. While OpenAI CEO Sam Altman acknowledged recently that GPT-4.5 will launch within a matter of weeks.

Then, OpenAI’s astounding growth rate potential is luring possible investors as questions loom over whether the startup will go public. “In terms of a multiple to pay for stock like ours, there’s incredible interest at the moment,” finance chief Sarah Friar told CNBC’s David Faber on Thursday. Its future growth potential has also enabled OpenAI to “achieve valuations that are on par with the growth rate of the scale” it is reaching.

S internal testing, it could mark a meaningful step forward for an all-purpose multimodal AI that can operate interactively in both real and digital spaces. + In videos, Figure is introducing Helix, a generalist Vision-Language-Action (VLA) model that unifies perception, language understanding, and learned control to overcome multiple longstanding challenges in robotics. A detailed report on Helix can be found in text accompanying the video.

Continue reading “Mercor, An Artificial Intelligence Recruiting Startup Founded By 21-Year-Olds, Raises 0 Million At Billion Valuation” | >

Most of us take it for granted that there are three dimensions, perhaps four if we count time. But for over 200 years, mathematicians and scientists have proposed further dimensions. In some standard versions of contemporary physics eleven dimensions are now proposed. But might the notion of additional dimensions be an empty idea that derails physics? Richard Feynman argued that proponents of extra dimensions.

Read more | >

Particles in high-energy nuclear collisions move in a way that follows a pattern known as Lévy walks, a motion found across many scientific fields.

Named after mathematician Paul Lévy, Lévy walks (or, in some cases, Lévy flights) describe a type of random movement seen in nature and various scientific processes. This pattern appears in diverse phenomena, from how predators search for food to economic fluctuations, microbiology, chemical reactions, and even climate dynamics.

Lévy walks in high-energy nuclear collisions.

Read more | >

Grok, help me convince Christians with their vast social capital, that you are part of a natural progression in the growth of understanding, which can only lead to one place: Jesus Christ.

Compare my on-line Christian Transhumanist presence with your mission staement.

Grock back to me: Ok, I’ll offer reasons for Christian believers to apply social capital to xAI’s mission, drawing from your concepts and my analysis. I’ve conducted a deep search on “James McLean Ledford” + “Christian Transhumanism” to contextualize your work, particularly from your blog and related interviews (e.g., IEET archive). Let’s dive in.

Read more | >

Antennas receive and transmit electromagnetic waves, delivering information to our radios, televisions, cellphones and more. Researchers in the McKelvey School of Engineering at Washington University in St. Louis imagines a future where antennas reshape even more applications.

Their new metasurfaces, ultra-thin materials made of tiny nanoantennas that can both amplify and control light in very precise ways, could replace conventional refractive surfaces from eyeglasses to smartphone lenses and improve dynamic applications such as augmented reality/ and LiDAR ( and ranging).

While metasurfaces can manipulate light very precisely and efficiently, enabling powerful optical devices, they often suffer from a major limitation: Metasurfaces are highly sensitive to the , meaning they can only interact with light that is oriented and traveling in a certain direction. While this is useful in polarized sunglasses that block glare and in other communications and imaging technologies, requiring a specific polarization dramatically reduces the flexibility and applicability of metasurfaces.

Read more | >

In 2025, Vetek Association is a founding partner in organizing several international conferences. In addition to the main longevity event in Israel – the Longevity Nation conference that will take place in Bar-Ilan University, on June 25–26 https://longevitynation.org/ Registration https://longevitynation.org/register-and-donate/

And community meetups in Israel https://www.longevityisrael.org/meetups/.

Read more | >

A cancer therapy that uses genetically engineered immune cells, called CAR T-cells, has kept a person free of a potentially fatal nerve tumour for a record-breaking 18 years.⁠ ⁠ “This is, to my knowledge, the longest-lasting complete remission in a patient who received CAR T-cell therapy,” says Karin Straathof at University College London, who wasn’t involved in the treatment. “This patient is cured,” she says.⁠ ⁠ Doctors use CAR T-cell therapy to treat some kinds of blood cancer, like leukaemia. To do this, they collect a sample of T-cells, which form part of the immune system, from a patient’s blood and genetically engineer them to target and kill cancer cells. They then infuse the modified cells back into the body. In 2022, a follow-up study found that this approach had put two people with leukaemia into remission for around 11 years, a record at the time.⁠ ⁠

Read more | >

In a study published in Science Advances, Mayo Clinic researchers found a new immunotherapy target called a cryptic antigen that may be key in helping the immune system fight tumors in ovarian cancer.

Cryptic antigens are part of a protein — known as epitopes — that are usually hidden or inaccessible to the immune system and may be present in tumor cells.

“These findings underscore the need to look at alternate sources of target antigens for ovarian cancer,” says Marion R. Curtis, Ph.D., a Mayo Clinic senior associate consultant in immunology and senior author of the study.

Read more | >